CNS Pharma has launched a fundraising drive for a phase 2 study of a drug for glioblastoma, the form of brain cancer that has claimed the lives of Senator Ted Kennedy and Vice President Joe Biden's son Beau.
The program is notable because it involves a drug in the well-established anthracycline class of cytotoxic chemotherapy agents that differs from its predecessors in one crucial aspect: It can cross the blood-brain barrier (BBB) designed to protect the central nervous system from toxic attack.
With so much attention on cancer immunotherapies at the moment, it's easy to gloss over the...
The comment you're trying to see no longer exists.
Republic does not verify information provided by companies on this Portal and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Portal can be found by searching the EDGAR database.